Lexaria Bioscience Corp 's ability to collect accounts receivable sequentially worsen to 0.87, indicating more challenging environment then in the second quarter 2026, but still, it is a far cry from any concerns. Lexaria Bioscience 's Accounts Receivable average collection period in the May 31 2026 quarter, has increased to 420 days, from 283 days, in the Feb 28 2026 quarter.

If we take a look into Healthcare sector Lexaria Bioscience Corp achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Lexaria Bioscience Corp Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LEXX Receivables Turnover Ratio	(May 31 2026) III. Quarter	(Feb 28 2026) II. Quarter	(Nov 30 2025) I. Quarter	(Aug 31 2025) IV. Quarter	(May 31 2025) III. Quarter
Y / Y Receivable Change	-68.44 %	-87.31 %	138.45 %	138.45 %	71.81 %
Y / Y Revenue Change	-	-88.51 %	-	107.14 %	107.14 %
Receivable Turnover Ratio (TTM)	0.87	1.29	1.46	2.33	2.47
LEXX's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	419	282	249	157	148
Seq. Receivable Change	168.89 %	-88.59 %	0 %	2.86 %	8.14 %
Seq. Revenue Change	-	-	-	0 %	0 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

LEXX Company Profile • Back to LEXX Efficiency Comparisons • Compare LEXX Receivables Turnover Ratio to its Competitors

Financial Statements
Lexaria Bioscience 's Accounts Receivable	$ 0 Millions	Visit LEXX's Balance sheet
Lexaria Bioscience 's Sales TTM	$ 0 Millions	Visit LEXX's Income Statement
Sources of LEXX's Revenues		Visit LEXX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
LEXX's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
LEXX's Growth Rates	LEXX's Roa	LEXX's Inventory Turnover Ratio	LEXX's Dividend Comparisons
LEXX's Profitability Ratios	LEXX's Roi	LEXX's Asset Turnover Ratio	LEXX's Dividend Growth
LEXX's Valuation Ratios	LEXX's Roe	LEXX's Financial Strength Ratios	LEXX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending May 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending May 31 2026	Receivable at quarter ending May 31 2026
Viatris Inc	4.68	$ 14,737.300 Millions	$ 3,151.350 Millions
Bausch and Lomb Corp	4.65	$ 5,324.000 Millions	$ 1,144.000 Millions
Davita Inc	4.64	$ 14,009.646 Millions	$ 3,018.719 Millions
Staar Surgical Co	4.63	$ 339.590 Millions	$ 73.350 Millions
Orasure Technologies Inc	4.62	$ 111.978 Millions	$ 24.227 Millions
Kura Oncology Inc	4.60	$ 77.225 Millions	$ 16.784 Millions
Yunhong Green Cti Ltd	4.58	$ 20.662 Millions	$ 4.513 Millions
Orthopediatrics Corp	4.56	$ 251.278 Millions	$ 55.123 Millions
Aligos Therapeutics Inc	4.54	$ 31.518 Millions	$ 6.945 Millions
Bioventus Inc	4.49	$ 581.106 Millions	$ 129.410 Millions
Bionexus Gene Lab Corp	4.48	$ 3.127 Millions	$ 0.697 Millions
Omniab Inc	4.48	$ 38.457 Millions	$ 8.588 Millions
Bellevue Life Sciences Acquisition Corp	4.47	$ 1.809 Millions	$ 0.404 Millions
Vaso Corporation	4.44	$ 80.220 Millions	$ 18.048 Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________	4.40	$ 25.185 Millions	$ 5.729 Millions
Neurocrine Biosciences Inc	4.40	$ 3,373.900 Millions	$ 767.475 Millions
Globus Medical Inc	4.33	$ 3,144.934 Millions	$ 726.626 Millions
Organon and Co	4.31	$ 6,139.000 Millions	$ 1,422.750 Millions
Alkermes Plc	4.30	$ 1,667.652 Millions	$ 388.132 Millions
Glaukos Corp	4.29	$ 500.031 Millions	$ 116.471 Millions
Lantheus Holdings Inc	4.24	$ 1,555.343 Millions	$ 367.122 Millions
Apyx Medical Corp	4.14	$ 58.105 Millions	$ 14.035 Millions
Regenxbio Inc	4.13	$ 174.482 Millions	$ 42.238 Millions
Inspiremd Inc	4.12	$ 10.502 Millions	$ 2.550 Millions
Nexalin Technology Inc	4.07	$ 0.217 Millions	$ 0.053 Millions
Medinotec Inc	4.07	$ 10.247 Millions	$ 2.519 Millions
Outset Medical Inc	4.06	$ 117.551 Millions	$ 28.959 Millions
Ironwood Pharmaceuticals inc	4.04	$ 389.316 Millions	$ 96.422 Millions
Pelthos Therapeutics Inc	4.03	$ 43.304 Millions	$ 10.757 Millions
Revvity Inc	4.03	$ 2,911.811 Millions	$ 723.421 Millions

Date modified: 2026-08-03T18:30:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.